Surveyed U.S. Physicians Indicate That Xarelto And Apixaban Will Benefit From The Lack Of Use Of A Fast-Acting Injectable Anticoagulant In The Treatment And Secondary Prophylaxis Of Deep Vein Thrombosis/Pulmonary Embolism
BURLINGTON, Mass., March 27, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish between current regimens utilized for the treatment and secondary prophylaxis of deep vein thrombosis (DVT)/pulmonary embolism (PE), as these regimens are initiated with use of a short-term injectable anticoagulant prior to long-term anticoagulation with warfarin. However, Bayer/Janssen's Xarelto and Bristol-Myers Squibb/Pfizer's Eliquis are expected to displace current therapies for the treatment and secondary prophylaxis of DVT/PE. Surveyed U.S. emergency room physicians indicate that Xarelto and Eliquis have competitive advantages in efficacy, safety and tolerability and delivery.
"We forecast that Xarelto will become the U.S. market leader in the treatment and secondary prophylaxis of DVT/PE, with a 22.4 percent patient share by 2021, closely followed by apixaban with 19.3 percent," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "This is due to these agents' impressive results in clinical trials, and the fact that oral therapy can be initiated straight away, removing the need to begin therapy with a fast-acting injectable anticoagulant."
The DecisionBase 2013 report entitled Therapies with Improved Safety and Delivery Profiles Are Set to Overtake Enoxaparin and Warfarin as Leading Treatments of DVT/PE also finds that surveyed U.S. and European emergency room physicians agree that the incidence of VTE-related mortality is one of the attributes that most influences their decisions regarding prescribing in the treatment and secondary prophylaxis of DVT and PE. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage on this attribute over the sales-leading regimen of enoxaparin (Sanofi's Lovenox, generics) plus warfarin (Bristol-Myers Squibb's Coumadin, Eisai's Warfarin, generics).According to insights from surveyed U.S. and European emergency room physicians and managed care organization (MCO) pharmacy directors, reducing the incidence of bleeding is one of the greatest unmet needs in the treatment and secondary prophylaxis of DVT/PE. Clinical data and the opinions of interviewed thought leaders indicate that the novel oral anticoagulants -- Xarelto, Eliquis, Boehringer Ingelheim's Pradaxa, Daiichi Sankyo's Lixiana -- have demonstrated the potential to partially fulfill this unmet need.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts